Please login to the form below
Suliqua
This page shows the latest Suliqua news and features for those working in and with pharma, biotech and healthcare.
Sanofi wins EU approval for new diabetes combination Suliqua
European Commission licenses the once-daily version of Lantus and Lyxumia. Sanofi's combination therapy Suliqua has been granted European marketing approval for the treatment of adults with type 2 diabetes. ... The approval of Suliqua represents the
Latest news
-
Gilead's hepatitis B virus treatment set for European approval
Suliqua, an insulin glargine and lixisenatide combination therapy, has been backed for the treatment of adults with type 2 diabetes. ... Backed for use in patients for whom metformin does not provide sufficient glycaemic control, Suliqua will be
More from news
Approximately 2 fully matching, plus 0 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2018
Suliqua &Lyxumia/ Adlyxin for Type 2 diabetes. Purchase of. royalty rights.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- bluebird bio reveals plans to launch two gene therapies
- AstraZeneca and MSD’s breast cancer drug Lynparza receives EC approval
- Eli Lilly to make bebtelovimab commercially available to US states from August
- Regeneron terminates four clinical trials of its COVID-19 antibody cocktail REGEN-COV
- The patient voice – the value of patient-reported outcomes in HTA
- Biogen and Eisai share latest lecanemab results for the treatment of Alzheimer's disease
- Strategic commitment
- Pfizer set to acquire Global Blood Therapeutics in deal worth $5.4bn
- AstraZeneca and Daiichi Sankyo get FDA approval for breast cancer drug
- NHS England launches hepatitis C screening scheme to reach 2030 elimination goal
- Bayer’s Nubeqa receives FDA approval to treat metastatic prostate cancer
- Valneva and Pfizer initiate phase 3 Lyme disease vaccine study
- Medmeme appoints Dr Joseph Laudano to medical affairs role
- Gilead announces positive Biktarvy data for HIV and hepatitis B
- Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection
- Sarepta to submit application for Duchenne muscular dystrophy gene therapy
- Achieving communication excellence by targeting the right channel at the right time
- Successful product commercialisation: what can we learn from the rare disease setting?
PMHub
McCann Health Medical Communications
We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....
Latest intelligence
- Strategic commitment
- ...
- KOL Ambassador Program & Podcast Creation: A Customer Story
- ...
- Animation: Living With
- The journey from the patient's perspective...
